Form 4 for ACXP Acurx Pharmaceuticals, Inc.
Accepted 2025-01-08 00:00:00 ET · period of report 2025-01-06 · accession 0001104659-25-002053 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-08 | 2025-01-06 | ACXP | Sailer Carl | Dir | P - Purchase | $1.02 | +24.6K | 137.2K | +22% | +$25.1K |
| D | 2025-01-08 | 2025-01-06 | ACXP | Sailer Carl | Dir | P - Purchase | $0.00 | +24.6K | 24.6K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-06 | P | A | 24,631 | $1.02 | 137,183 | D | — | — | (F1) Acquired at the offering price in a registered direct offering of common stock by Acurx Pharmaceuticals, Inc. |
| 2 | Derivative | Warrants for Common Stock | 2025-01-06 | P | A | 24,631 | $0.00 | 24,631 | D | $0.9 · 2025-01-07 to 2030-01-07 | 24,631 Common Stock | (F2) Acquired in a concurrent private placement of warrants by Acurx Pharmaceuticals, Inc. in connection with the registered direct offering of common stock. |